| Literature DB >> 31218417 |
B Stephan1, M A Radtke2, M Augustin2.
Abstract
Systemic therapy of pregnant patients with psoriasis requires special attention and has to be adapted to disease activity throughout the pregnancy. With the approval of the first tumor necrosis factor alpha inhibitors for the treatment of these patients, a new range of options has to be discussed with the women. If the inflammatory presentation of the psoriasis demands systemic therapy, the decision for treatment should be made as early as possible, preferably before the onset of pregnancy.Entities:
Keywords: Active inflammation; Biological products; Desire to have children; Immunomodulatory therapy; TNF-alpha inhibitors
Mesh:
Substances:
Year: 2019 PMID: 31218417 DOI: 10.1007/s00105-019-4444-2
Source DB: PubMed Journal: Hautarzt ISSN: 0017-8470 Impact factor: 0.751